Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease

Translational Psychiatry

Volumn 5, Issue 1, 2015, Pages

  Proitsi, P ^a   Kim, M ^a   Whiley, L ^a   Pritchard, M ^a   Leung, R ^a   Soininen, H ^b   Kloszewska, I ^c   Mecocci, P ^d   Tsolaki, M ^e   Vellas, B ^f   Sham, P ^g   Lovestone, S ^h   Powell, J F ^a   Dobson, R J B ^a,i   Legido Quigley, C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UNIVERSITY OF PERUGIA   (Italy)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f Faculté de Médecine Centre Hospitalo universitaire   (France)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; CHOLESTEROL ESTER;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; CHOLESTEROL METABOLISM; CONTROLLED STUDY; FEMALE; HUMAN; LIPIDOMICS; MAJOR CLINICAL STUDY; MALE; METABOLITE; MILD COGNITIVE IMPAIRMENT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CASE CONTROL STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; CASE-CONTROL STUDIES; CHOLESTEROL ESTERS; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; MULTIVARIATE ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84927928846     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.127     Document Type: Article

References (38)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005; 366: 2112-2117
2. Whiley L, Legido-Quigley C. Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease. Bioanalysis 2011; 3: 1121-1142
3. Samson K. MEDICARE panel: Too little evidence to show amyloid PET scans improve Alzheimer outcomes. Neurol Today 2013; 13: 36-42
4. Whiley L, Godzien J, Ruperez FJ, Legido-Quigley C, Barbas C. In-vial dual extraction for direct LC-MS analysis of plasma for comprehensive and highly reproducible metabolic fingerprinting. Anal Chem 2012; 84: 5992-5999
5. Lindon JC, Holmes E, Nicholson JK. Metabonomics in pharmaceutical R&D. FEBS J 2007; 274: 1140-1151
6. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wagele B et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011; 477: 54-60
7. Suhre K, Meisinger C, Doring A, Altmaier E, Belcredi P, Gieger C et al. Metabolic footprint of diabetes: A multiplatform metabolomics study in an epidemiological setting. PLoS One 2010; 5: e13953
8. Barba I, Fernandez-Montesinos R, Garcia-Dorado D, Pozo D. Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. J Cell Mol Med 2008; 12: 1477-1485
9. Lunnon K, Ibrahim Z, Proitsi P, Lourdusamy A, Newhouse S, Sattlecker M et al. Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. J Alzheimers Dis 2012; 30: 685-710
10. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007; 28: 977-986
11. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011; 6: e21643
12. Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 2009; 30: 1235-1239
13. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J Lipid Res 2012; 53: 567-576
14. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Macarthur LH et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20: 415-4182014
15. Oresic M, Hyotylainen T, Herukka SK, Sysi-Aho M, Mattila I, Seppanan-Laakso T et al. Metabolome in progression to Alzheimer's disease. Transl Psychiatry 2011; 1: e57
16. Whiley L, Sen A, Heaton J, Proitsi P, Garcia-Gomez D, Leung R et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging 2014; 35: 271-278
17. Reitz C. Dyslipidemia and the risk of Alzheimer's disease. Curr Atheroscler Rep 2013; 15: 307
18. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 2014; 88: 640-651
19. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-1093
20. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-435
21. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al. Genomewide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-1099
22. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452-1458
23. Astarita G, Jung KM, Vasilevko V, Dipatrizio NV, Martin SK, Cribbs DH et al. Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease. PLoS One 2011; 6: e24777
24. Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 2012; 287: 2678-2688
25. Hejazi L, Wong JW, Cheng D, Proschogo N, Ebrahimi D, Garner B et al. Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochem J 2011; 438: 165-175
26. Wisniewski T, Newman K, Javitt NB. Alzheimer's disease: brain desmosterol levels. J Alzheimers Dis 2013; 33: 881-888
27. Lovestone S, Francis P, Strandgaard K. Biomarkers for disease modification trials-the innovative medicines initiative and AddNeuroMed. J Nutr Health Aging 2007; 11: 359-361
28. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127
29. Butovich IA. Fatty acid composition of cholesteryl esters of human meibomian gland secretions. Steroids 2010; 75: 726-733
30. Butovich IA, Uchiyama E, McCulley JP. Lipids of human meibum: massspectrometric analysis and structural elucidation. J Lipid Res 2007; 48: 2220-2235
31. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 2004; 44: 227-238
32. Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousselet E et al. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci USA 2010; 107: 3081-3086
33. Murphy SR, Chang CC, Dogbevia G, Bryleva EY, Bowen Z, Hasan MT et al. Acat1 knockdown gene therapy decreases amyloid-beta in a mouse model of Alzheimer's disease. Mol Ther 2013; 21: 1497-1506
34. de Vries R, Borggreve SE, Dullaart RP. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab 2003; 49: 601-613
35. Barter P, Rye KA. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now? Trends Pharmacol Sci 2011; 32: 694-699
36. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 160-167
37. Greeve I, Kretzschmar D, Tschape JA, Beyn A, Brellinger C, Schweizer M et al. Agedependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci 2004; 24: 3899-3906
38. Crameri A, Biondi E, Kuehnle K, Lutjohann D, Thelen KM, Perga S et al. The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J 2006; 25: 432-443.